Livtencity Approved for Post-Transplant Cytomegalovirus Infection
Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.
Outpatient Gabapentin Rarely Used for Approved Indications
Concomitant use of central nervous system-depressant drugs listed for 58.4% of off-label gabapentin visits
Multidose Vial Presentation of Audenz, an H5N1 Influenza Vaccine, Approved
Audenz is an inactivated cell-based influenza vaccine that contains MF59, a proprietary adjuvant.
Fyarro Approved for Malignant Perivascular Epithelioid Cell Tumor
The approval of Fyarro, an mTOR inhibitor, was based on data from the phase 2 AMPECT study, which included 34 adults with advanced malignant PEComa.
Bimekizumab Significantly Improves Joint, Skin Symptoms in Psoriatic Arthritis
The phase 3 BE OPTIMAL study included 852 adults with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug naïve.
Study Investigates Rate of Antidrug Antibody Formation to Biologics Used in IBD
Given that immunogenicity to biologics may contribute to IBD treatment failure, the study authors sought to determine the rate of ADA formation to individual biologic agents.
Growing Evidence Links Pentosan Polysulfate Sodium, Maculopathy
Specific retinal conditions proportionately more common for PPS users versus users of other interstitial cystitis, bladder pain drugs
Annual Mammography Not Cost-Effective Beyond 75 Years
Extending biennial mammography from age 75 to 80 years is cost-effective, but the absolute number of deaths averted is small
Risk for Stillbirth Elevated for Deliveries With COVID-19
Adjusted relative risk for stillbirth higher in deliveries with COVID-19 in pre-delta and delta periods, with stronger link during delta period
Thirty Percent of Hospital-Based Health Care Personnel Unvaccinated
COVID-19 vaccination coverage increased from 36.1 to 60.2 percent from January to April 2021, then slowed, reaching 70.0 percent as of Sept. 15
